Steve Christ | Corbis News | Getty Images
The version of this article first appeared at the CNBC Bulletin Bulletin Healthy Returns, which brings the latest news of health care straight to your inbox. Subscribe here to receive future editions.
Novo NordiskDrugs for diabetes blockbuster ground can also help people drink less alcohol.
It is according to the new government research Posted in Psychiatry Caves Last week.
It was a small study of only 48 adults who lasted for more than two months, but it seems to be the first clinical trial that confirmed that so-called GLP-1 drugs can help reduce the risk of too much alcohol. More real -world data analyzes, along with studies In animals, they suggested that relationship.
The findings could be huge for those who have a disorder of alcohol use, which is when a person cannot stop drinking even when their health and safety threatens. The situation affects nearly 30 million people in the United States -Us covers what people are mostly called alcohol abuse, alcohol or alcohol dependence, according to to a national research on drug and health use of 2023.
The use of alcohol makes up 2.6 million deaths a year and increases the risk of common diseases such as different cancers, the study authors wrote. Three drugs were already approved for alcohol use disorders, but the authors said that only a small proportion of patients with this condition received treatment.
New data adds increasing evidence that GLP-1, such as Oskempic and his weight loss colleague Wegovy, can help people manage craving not only for food and alcohol.
Some preliminary research suggests drugs May muffled the craving For smoking, opioid use, gambling and excessively buying gambling activation of the brain of reward. GLP-1S Mimic hormones produced in the intestines for suppressing a person’s appetite and regulating blood sugar.
But larger and longer studies will need to confirm the effect of these drug addiction.
Let’s dive into the data.
Researchers recruited people between the ages of 21 and 65 who reported the symptoms of alcohol use disorders but did not actively seek treatment. Patients with diabetes and those who previously used GLP-1 or other weight loss medicines were off from the study.
Patients spent two hours in a laboratory room supplied with preferred alcoholic beverages – once before they started taking any medicines in the study and once they saw what had changed. About half of the people took low doses of semaglutides, an active ingredient in Orempic, and half received placebo shootings over nine weeks.
They also reported their drinking habits and a desire for alcohol throughout the study.
The results suggested that the traffic lights reduced weekly cravings for alcohol, reducing the average number of drinks spent during the drinking day and led to a greater reduction in the days of heavy drinking compared to placebo. Significant is that the effect of Oskempic on suppression of several drinking outcomes is greater than what is often seen in existing drugs that aim to reduce the craving for alcohol.
By the second month of the study, people who took Oskempic were on average drinking 30% less. This is compared to an average reduction of about 2% in the placebo group.
Almost 40% of the people who took Oskempi reported that there was no big drinking in the second month of treatment, compared to 20% in the placebo group.
The study’s authors noted that they used the two lowest clinical doses of semaglutides in the examination. Higher doses of the drug “would probably give greater effects on alcohol reduction,” they added.
“These data suggest the potential of semaglutides and similar drugs to fulfill the dissatisfied need for the treatment of alcohol disorders,” said Senior author Klara Klein of the Faculty of Medicine, University of North Carolina UA statement. “Larger and longer studies of the wider population are needed to fully understand safety and efficiency in people with alcohol use disorders, but these initial finds promise.”
Among the small subgroups of people who smoked, those who took Oskempic had a significantly greater reduction in average cigarettes a day compared to those from the placebo group. This suggests that Orempic can reduce both alcohol and nicotine.
Eli Lilly Studying plans for weight loss medicines to help treating addictive behaviors such as alcohol and drug abuse. The company announced that great clinical trials would begin in 2025.
Feel free to send any tips, suggestions, ideas and stories information in Annika Annikakakim.constantino@nbcuni.com.
The latest in health technology: primary care doctors are concerned about patients approaching GLP-1 through third-party telehesion providers, says the poll
Box of the ground and content sits on a table in Dudley, North Tyneside, Britain, October 31, 2023.
George Frey | Reuters
As the demand for blockbuster GLP-1 has leaned weight loss remedies in recent years, some patients turned to digital health companies like HIMS & HERS Health, ro, sesame and night for medication access. Primary care doctors don’t think it’s such a good idea.
Released metabolic health startup omda poll of more than 2,000 primary care physicians last week who estimated their attitude towards GLP-1 and various treatment plans. Generally, doctors said they were concerned about third -party telephonual services.
Less than 20% of doctors surveyed said they would be comfortable with patients using third party service providers to access GLP-1. Two -thirds of the respondents said that they agree that access to recipes through a third -party telehesion provider could endanger patients’ health.
“That was alarming, I didn’t even think it would be so tall,” President Omada Wei-Li Shao told CNBC in an interview.
Omada does not prescribe GLP-1, but the company offers an accompanying program that supports patients taking medication. It also aims to help patients maintain weight loss if they decide to stop taking medication.
The company has found that primary doctors are generally concerned about third -party telephony services for two reasons: excessive prescribing and continuity of care. In other words, they are worried that patients could access GLP-1 when it is not clinically appropriate and may not get the necessary support through additional touch points like further visits.
In addition, many survey doctors are on the fence on the role of complex GLP-1, which are adapted to alternatives to medicines with brands intended to meet the specific needs of the patient. Complex drugs can also be produced when treatments with brand brand lack.
The FDA does not examine the safety and efficiency of complex products, but they can serve as an alternative to the branded drugs for patients moving with complex obstacles to supply and lean insurance.
About 45% of interviewed doctors said that the complex GLP-1 would not be a long-term supply strategy, although they agreed that they could be of help to deal with current defects. And 30% of respondents said they agreed or strongly agreed that they were comfortable with the complex GLP-1.
“Patients or people looking for solutions are confused,” Shao said. “What our position is to talk to your doctor, talk to a primary care doctor, who knows you, knows your history, knows what you were and know what your goals are and has a perspective of what is the right treatment in partnership with you.”
Read the whole report here.
Feel free to send all tips, suggestions, ideas and information about Ashley stories ashley.capoot@nbcuni.com.
Health plans clash with the cost of therapy of new sickle cells
It’s been just over a year since the FDA has approved the therapy of Srpa cell gene therapy. But in some ways, the breakthrough of medication is still waiting to deal with patients on a scale.
With more than half of patients with sickle cells covered with medicalide, the expansion of covering for the therapy of sickle cells could be difficult. States are already facing high medical costs in a joint program with the Federal Government and are advocated by the potential reduction of Congress funding. Private insurers also face higher medical costs.
CVS health Executive director David Joyner told me that private and state health plans look at new ways to manage the cost of breakthrough gene therapies.
Feel free to send any tips, suggestions, ideas and stories information Bertha.coombs@nbcuni.com.
